CNBC's Meg Tirrell reports on what bio-pharma breakthroughs to expect out of this year's ASCO conference, and the "FMHR" traders weigh in on the biotech sector.
Dennis Davitt, Harvest Volatility Advisors, and Rich Ross, Evercore ISI, discuss the biotech sector with Melissa Lee.
Saker Nusseibeh, CEO of Hermes Investment Management, recommends the theme of intellectual property, such as IT and pharma stocks, to investors.
The "FMHR" traders discuss the rebound in the biotech sector and give some picks.
Dennis Gartman, founder, editor & publisher of The Gartman Letter, comments on Monsanto's decision to reject the Bayer acquisition proposal.
A start-up is giving its employees a new Tesla car, which is expected to cost $35-thousand each.
Kurt Graves, Intarcia Therapeutics CEO, discusses how the company's product eliminates the need for daily injections for type 2 diabetes and instead delivers a steady dose of medicine over the course of a year,
CNBC's Mary Thompson looks ahead at the day's market action including energy stocks and surging oil prices.
Sanofi will nominate eight people to replace the board of Medivation, sources say.
CNBC's Dominic Chu; Jim Iuorio, Managing Director at TJM Institutional Services; and David Seaburg, Managing Director and Head of Sales & Trading at Cowen & Company, discuss top fear trades on this Friday the 13th.
MIT researchers are developing a device that could one day help patch internal wounds, deliver medicine or remove accidentally swallowed objects from the stomach.
Dr. Andre Choulika, Cellectis CEO, discusses how gene editing could lead to a new way to fight cancer.
Discussing the impact of biotech deals on the sector overall, and whether Sanofi's offer for Medivation will pass, with Michael King, JMP Securities, and Les Funtleyder, E Squared Capital.
Sam Isaly, OrbiMed Advisors founder, discusses health care industry stock picks.
Martin Shkreli, former CEO of Turing Pharmaceuticals, will appear in at the U.S. District Court in Brooklyn Tuesday following December's seven-count indictment, reports CNBC's Meg Tirrell.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
Sarepta Therapeutics shares soared Monday after the stock was upgraded to "outperform" at Oppenheimer.
Jesper Brandgaard, CFO of Novo Nordisk, discusses the pharmaceutical company's earnings results and the impact of the declining dollar.
Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
Potential market cap swings in biotech with CNBC contributor Dan Nathan.